Generic Name |
||
---|---|---|
IND |
SF1126 | |
Brand Name (US) |
||
Manufacturer |
Semafore | |
Drug Type |
Congugate, prodrug | |
Delivery |
Intravenous | |
Approval Status |
Phase 1 | |
Indications |
||
Overall Strategy |
Oncogenic Signal Path Based | |
Strategy |
Block KIT Signal Path | |
Drug Category |
PI3K inhibitor |
Semafore Pharmaceuticals, a small company in Indianapolis, Ind. has developed a broad spectrum PI3K inhibitor based on the lab drug LY294002. SF1126 is a Prodrug that inhibits Class IA PI3Ks and DNA-PK and mTOR. A Prodrug is given in one form and converted into a different, active form by metabolic action in the body. Semafore has designed SF1126 to have an affinity for the vascular forming areas of tumors.
1/12/2012 "Semafore Pharmaceuticals (Indianapolis, IN) a drug discovery and development company focused on small molecule modulators of the PI3 Kinase (PI3K) & PTEN cell signaling pathway has raised $9.5M in Series B funding led by Twilight Venture Partners."